March 2, 2018
The Japanese ethical drug market shrank 1.0% to 10,514,878 million yen in 2017 on an NHI price basis, logging the first year-on-year drop since 2010, with Gilead Sciences’ hepatitis C drug Harvoni (ledipasvir + sofosbuvir) disappearing from the top 10...read more